These findings suggest that the dual inhibition of XPO1 and BCL2 effectively enhances apoptosis and disrupts mitochondrial integrity in myeloma cells, making this combination a promising therapeutic strategy for targeting myeloma. Here, XPO1 is linked to plasma cell myeloma.